Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Simplified insulin delivery devices are drawing renewed clinical interest as an alternative to increasingly complex automated insulin delivery (AID) systems, offering patients injection-free mealtime and basal dosing without the programming burden of a full pump.

New Patch Pump Options Highlighted at ADCES 2026

, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed new patch pump technology showcased at the 2026 conference of the Association of Diabetes Care & Education Specialists (ADCES). The discussion centered on emerging devices from Modular Medical and CeQur.

Watch the full episode, featuring tech, screening, and care updates from ADCES 2026,

Modular Medical's Pivot pump is a tubeless patch, worn for ≤3 days, holding ≤300 units of insulin. Each button press delivers a fixed 2-unit bolus, without carbohydrate counting or a bolus calculator. Unlike single fixed-rate devices such as V-Go, Pivot allows clinicians to program 2 distinct basal rates, adding flexibility while keeping the interface simple.

CeQur's Simplicity patch, previously limited to 3-4-day wear and 2-unit dosing, has moved toward an extended 7-day wear time with capacity ≤240 units and a new 1-unit dosing option for finer titration. Because Simplicity delivers mealtime insulin only, it still requires a separate long-acting basal insulin, positioning it as a potential companion to once-weekly basal insulins and incretin therapies as those agents reach the market. Combining these once-weekly options with Simplicity could let patients consolidate several therapies into a single day of dosing each week.

Modular Medical has indicated plans to pursue full automation for Pivot by partnering with a sensor and dosing algorithm, a step expected to require additional development, clinical study, and regulatory review over approximately 2 years. In the meantime, both devices reflect a countervailing trend in diabetes technology, prioritizing simplified, lower-burden insulin delivery for patients on multiple daily injections not seeking full automation.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Modular Medical. Modular Medical Announces Launch of Pivot Insulin Delivery System Across Five Key U.S. Markets Beginning October 2026. 

. August 3, 2026. Accessed August 11, 2026. 

https://www.biospace.com/press-releases/modular-medical-announces-launch-of-pivot-insulin-delivery-system-across-five-key-u-s-markets-beginning-october-2026

CeQur Simplicity. Extended 7-Day Wear and 1-Unit Dosing Clearances, and Two ADA Posters Signal a New Standard for Mealtime Insulin Management. June 4, 2026. Accessed August 11, 2026. 

https://myceqursimplicity.com/cequr-announces-exciting-advancements-2-recent-fda-clearances-and-new-clinical-evidence-to-be-presented-at-ada/

Videos

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new insulin pump technology presented at ADCES 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Type 1 Diabetes

Jay Lieberman, MD, from University of Tennessee

Two newly published reviews outline barriers to timely epinephrine use in 

among infants and toddlers and support incorporating age-specific signs into recognition criteria.

Current National Institutes of Health anaphylaxis criteria have not been updated to include infant-specific presentations for frontline clinicians, even as newer international definitions already incorporate them.

"Children, specifically infants and toddlers, can have different reactions or can look different during severe allergic reactions," said Jay Lieberman, MD, professor at the University of Tennessee Health Science Center and program director of the Allergy/Immunology Fellowship Program at Le Bonheur Children's Hospital, in an interview with 

Age-Specific Criteria Improve Anaphylaxis Detection in Infants

Recognizing Atypical Anaphylaxis Signs in Infants and Toddlers

Infants and toddlers cannot verbalize early symptoms such as oral or throat itching the way older children and adults can, which often delays recognition, Lieberman said. Because of this, clinicians and caregivers need to watch for nonverbal cues signaling a systemic allergic reaction. These cues include increased fussiness, inconsolable crying, clinging to a caregiver, placing a finger in the mouth to indicate oral or throat itching, and tugging at an ear to indicate itching inside the ear canal, according to Lieberman.

The plain language review by Pistiner et al, published in Expert Review of Clinical Immunology, identifies additional age-specific signs worth incorporating into recognition criteria, including drooling, back arching, belly breathing, and tongue-thrusting or licking behaviors.¹ Gastrointestinal symptoms such as vomiting are also commonly overlooked in this age group, as clinicians and caregivers may attribute them to a minor illness rather than an allergic reaction, Lieberman said.

Impact of Age-Specific Criteria on Anaphylaxis Detection

Why is anaphylaxis harder to recognize in infants and toddlers?

Infants and toddlers cannot verbalize symptoms and instead show nonverbal behavioral cues such as fussiness, ear tugging, and finger-in-mouth behavior.

How much do age-specific criteria improve anaphylaxis detection?


A plain language review found modified criteria improved detection by 23% in infants and 10% in toddlers compared with standard criteria.

What is the biggest barrier to epinephrine use in young children?


According to Leeds et al, gaps in caregiver recognition and confidence, not epinephrine access alone, are key drivers of underuse.²

The review by Leeds et al. found modified age-specific anaphylaxis criteria improved detection by 23% in infants and 10% in toddlers compared with standard criteria.2 In practice, Lieberman said allergists and emergency physicians often rely on clinical judgment rather than a strict checklist when deciding to give epinephrine. Awareness of these additional presenting signs makes clinicians more likely to identify a reaction as anaphylaxis and to use epinephrine sooner, he said.

Leeds and colleagues analyzed more than a decade of literature to identify barriers behind delayed or missed epinephrine use in this age group.² Investigators point to gaps in caregiver recognition and confidence, rather than epinephrine access alone, as key drivers of delayed or missed treatment among infants and toddlers.

“If you're doing a food challenge or you have a patient with a food allergic reaction in the community, if it's an older kid or an adult, they can usually tell you, ‘Oh, I'm starting to have some itching in my mouth, or my throat feels a little funny,’ whereas an infant or toddler may not be able to tell you that,” Lieberman said, “and so, they're doing other things or behaving differently as that first sign.”

Pistiner et al. Recognizing and Treating Serious Allergic Reactions (Anaphylaxis) in Infants and Toddlers: A Plain Language Review of Four Studies. 

Leeds et al. Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians. 

New reviews outline barriers to epinephrine use and support age-specific anaphylaxis recognition criteria in infants and toddlers, says Jay Lieberman, MD.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Rima Rachid, MD, from Boston Children’s Hospital.

Antibiotic pretreatment before oral fecal microbiota transplantation (FMT) raised the peanut allergy response rate to 60% compared with 30% without pretreatment in a phase 1 trial of adults with severe 

Omalizumab is now the only FDA-approved option for peanut allergy, following the discontinuation of Palforzia oral immunotherapy on July 31, 2026, and even it lacks evidence of durable disease modification once therapy stops.

Investigators at Boston Children's Hospital tested FMT from healthy, non-allergic donors as a potential alternative in this phase 1 open-label trial.

Antibiotic Pretreatment Improves FMT Response in Peanut Allergy

“There is really no evidence right now that peanut oral immunotherapy can be a disease modifier, meaning that if you stop it, your disease will actually get better,” said Rima Rachid, MD, director of the Food Allergy Program and the Allergen Immunotherapy Program, Boston Children's Hospital, in an interview with 

FMT Response Rates with and without Antibiotic Pretreatment

The phase 1 open-label trial enrolled 15 adults aged 18 to 40 years with peanut allergy confirmed by reactivity to ≤ 100 mg of peanut protein on a double-blind, placebo-controlled food challenge. Participants received 36 capsules of oral encapsulated FMT from 1 of 3 screened, non-atopic donors, dosed incrementally over 1 day for most participants.¹

The first 10 participants (part A) received FMT without antibiotic pretreatment. Three of 10 (30%; 95% confidence interval [CI], 6.7%-65.3%) achieved a threshold increase to 300 mg or 600 mg of peanut protein at 1 or 4 months.

An additional 5 participants (part B) received oral vancomycin, neomycin, and metronidazole for 4 days before FMT. In total, 3 of 5 (60%; 95% CI, 14.7%-94.7%) achieved the same efficacy threshold. Overall, 6 of 15 participants (40%; 95% CI, 16.3%-67.7%) responded after a single FMT dose, with the response persisting at 4 months in all 6; 5 of the 6 responders were male, compared with 2 of 9 nonresponders (

FMT was well tolerated across the 15 participants. Three adverse events in grades 1 and 2 occurred, consisting of fatigue, diarrhea, nausea, abdominal pain, dizziness, and headache, all resolving within 12 to 48 hours. No grade 3 or higher events occurred, and no allergic reactions were attributed to FMT administration.¹

Sex-Based Response Differences in FMT for Peanut Allergy

Rachid said that she cannot yet jump to any conclusions about the apparent sex-based difference in response. She just noted it was “interesting as an observation.”

“We will need larger studies to see if there are indeed sex differences,” she said. “It’s too early to be certain. The larger studies will require a much larger number of patients… probably 1 donor per 20 patients. This is really scratching the tip of the iceberg. In this particular study, it is showing us a very promising signal, but as usual in research, it will bring a lot of questions once we have the data.”

Rachid R, Martinez-Blanco M, Kuziel GA, et al. Fecal microbiome transplant in food allergy in humans and mice identifies a role for bile acid metabolites in oral tolerance. 

Boston Children's Hospital. How 'good' bacteria from fecal transplants reduce peanut allergy. Published August 5, 2026. Accessed August 11, 2026. 

medicalxpress.com/news/2026-08-good-bacteria-fecal-transplants-peanut.html

HCPLive. Fecal Microbiota Transplant Boosts Peanut Tolerance in Phase 1 Trial. Published August 11, 2026. Accessed August 11, 2026. 

hcplive.com/view/fecal-microbiota-transplant-boosts-peanut-tolerance-phase-1-trial

Wood and Ross. Palforzia Discontinued, Ending the Only FDA-Approved Peanut OIT Option. HCPLive. Published July 31, 2026. Accessed August 5, 2026. 

https://www.hcplive.com/view/palforzia-discontinued-ending-only-fda-approved-peanut-oit

Rima Rachid, MD, discussed why antibiotic pretreatment before fecal microbiota transplantation may improve peanut allergy response rates.

Food Allergy

The American Academy of Dermatology (AAD) issued its first pediatric-specific 

 guidelines in 2026, covering primary prevention and comorbidity awareness for children with the disease.¹ The prevention guideline gives moisturizers a conditional recommendation to reduce eczema occurrence in children aged 6 months to 3 years, while water softeners and dust mite avoidance showed no preventive benefit.¹

Eosinophilic esophagitis carries the only high-certainty comorbidity link to pediatric atopic dermatitis, with moderate-certainty evidence connecting the disease to allergic rhinitis, asthma, food allergy, urticaria, and ADHD.¹ Pediatric access to non-steroidal topicals has also widened. Tapinarof cream 1% gained 

 approval for children as young as 2 years in December 2024, adding an aryl hydrocarbon receptor agonist to the pediatric toolkit.²

Roflumilast cream 0.05% followed in October 2025 for children aged 2 to 5 years, with the phase 3 INTEGUMENT-PED trial showing 25.4% of treated children reaching treatment success at week 4 versus 10.7% on vehicle.³

These approvals carry real clinical weight because many families arrive concerned about topical steroid use and end up undertreating their child's eczema as a result. A broader menu of nonsteroidal options, spanning several drug classes and now reaching a wider pediatric age range, gives clinicians more flexibility to match therapy to a family's needs.

Lawrence Eichenfield, MD, is chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and vice chair of the department of dermatology at the University of California, San Diego. He reviewed these updates during a Maui Derm session titled ‘Atopic Dermatitis and Itch Update 2026.’ In the following Q&A interview segment, Eichenfield discusses why the pediatric guidelines and expanding topical options matter for clinicians:

: Why was this session on atopic dermatitis and itch important to highlight for clinicians?

There is an incredible amount happening in atopic dermatitis along the spectrum of ages we treat, and the therapeutic agents we're using are changing. They've morphed every year, with new agents, new information, and new experiences. For this session, I divvied up the activities with my co-presenter [UNCLEAR — please review], and my job was to review pediatric atopic dermatitis and the new changes in topical medications, then look from a pediatric perspective at the changes happening in systemic medicine. There's really just a ton of new information.

What were the key pediatric-focused topics from the session you feel are most important for clinicians?

 The American Academy of Dermatology never had specific pediatric atopic dermatitis guidelines, and now we do. That information was put out in two different papers, and they're really important for people to know about. The first one, which a lot of people might not be aware of because it's not as much a direct therapy paper, was a paper on prevention of atopic dermatitis and consideration of comorbidities, and it raised several issues we face with patients.

I structured some of the answers in this evidence-based guideline around questions patients might have. For instance, can you prevent atopic dermatitis with the use of moisturizers? That's been a highly controversial topic over the years, because we have some studies showing the ability to decrease rates of development of atopic dermatitis and others that don't. We discussed there's some conditional evidence that moisturizer may help prevent atopic dermatitis, and I went through some very interesting recent studies showing benefits of moisturizer to prevent atopic dermatitis, though maybe less in patients who already have a family history of the disease.

One big study was by Eric Simpson, and another out of Ireland showed a higher ability to decrease atopic dermatitis when moisturizers were started very early. Still, it's a conditional recommendation, and the basis of evidence isn't that strong. We also discussed other prevention strategies that didn't pan out: water softeners don't prevent atopic dermatitis, and neither does dust mite avoidance.

Then I went through the comorbidity listing, which is really important from an eczema standpoint. Allergic comorbidities are highly associated with eczema. Certain autoimmune diseases, including alopecia areata or [UNCLEAR — please review], are considered comorbidities of atopic dermatitis, and there's also data on bone health, though the evidence is actually uncertain from a pediatric standpoint.

Then I moved on to new therapies. We've had an extension of approval of non-steroids in pediatrics over the past year or two, including several within just a few months. Topical ruxolitinib has been approved down to 2 years of age; we need a little more data, but with a maximal 20% body surface area rule, it can be really helpful in our practices and has very good safety data. Topical tapinarof is also approved down to 2 years of age, with some very high efficacy data. Topical roflumilast has been developed in different concentrations: it was approved for ages 6 and up in a 0.15% cream, and now for 2- to 5-year-olds in a .05% cream.

We also reviewed infant data presented for the first time a few months ago at the American Academy of Dermatology meeting. The drug isn't yet approved in that age group, but in a study of children 3 months to 2 years old, it showed really good data on utility. In a novel approach, the researchers also looked at scalp disease, which I really like, and showed nice improvement in global scalp dermatitis in patients who had it.

Lastly, I briefly touched on delgocitinib, which has been approved for chronic hand eczema in adults; studies have been done in teens, and we believe we're going to see changes in the topical world for that age group within the next few months.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis. J Am Acad Dermatol. 2026;95(1):124.e1-124.e19. 

Organon. FDA approves VTAMA (tapinarof) cream, 1% for the treatment of atopic dermatitis in adults and children 2 years of age and older. Published December 16, 2024. Accessed August 11, 2026. 

https://www.organon.com/news/fda-approves-vtama-tapinarof-cream-1-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-2-years-of-age-and-older/

Arcutis Biotherapeutics. FDA approves Arcutis' ZORYVE (roflumilast) cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5. Published October 6, 2025. Accessed August 11, 2026. 

https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5/

Articles

First pediatric-specific AAD atopic dermatitis guidance (2026) addresses primary prevention and comorbidity surveillance. Moisturizers receive a conditional recommendation for reducing incident eczema in children 6 months–3 years, whereas water softeners and dust mite avoidance show no preventive benefit. Eosinophilic esophagitis is the lone high-certainty comorbidity; allergic rhinitis, asthma, food allergy, urticaria, and ADHD have moderate-certainty associations. Pediatric nonsteroidal topical options have expanded with tapinarof, roflumilast (INTEGUMENT-PED: 25.4% vs 10.7% week-4 success), and ruxolitinib, supporting individualized care amid steroid hesitancy concerns.

This Q&A highlights recent data and FDA approvals described in the pediatric atopic dermatitis space by Lawrence Eichenfield, MD.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Q&A: First Pediatric Eczema Guidelines and New Topical Options Down to Age 2

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

 classification is entering a period of active revision. Data continue to challenge how clinicians define phenotype, stage disease, and time treatment, particularly as heart failure with preserved ejection fraction closes in on heart failure with reduced ejection fraction in US prevalence.

Two clinical forums, one moderated by Ali Valika, MD, in Chicago and another by Orly Vardeny, PharmD, MS, FHFSA, FAHA, FCCP, in Minneapolis, brought clinicians together around a shared question: how can earlier recognition and phenotype-guided treatment reduce cardiovascular risk and heart failure burden?

Credit: Orly Vardeny, PharmD, on LinkedIn

Heart Failure Prevalence and Evolving Staging Frameworks

Both sessions opened with epidemiology that framed the stakes. An estimated 56 million people worldwide and roughly 7 million adults in the US live with heart failure, with a lifetime risk near one in four and an annual cost approaching $108 billion driven largely by hospitalization.¹ Participants in both cities noted that heart failure with reduced ejection fraction remains the more common global diagnosis, but in the US, preserved ejection fraction has caught up, or in some practices overtaken it, a shift linked to rising rates of obesity and metabolic syndrome.

Valika walked Chicago participants through standard heart failure staging, noting that stage C captures most symptomatic patients while stage A and stage B remain poorly defined in everyday practice. In Minneapolis, Vardeny introduced the cardiovascular-kidney-metabolic staging framework recently released by the American Heart Association, which layers onto traditional heart failure stages and asks clinicians to account for overlapping obesity, diabetes, and chronic kidney disease rather than treating heart failure in isolation. Vardeny also noted that an updated framework for classifying heart failure phenotype is expected within months, a signal that current ejection fraction cutoffs may soon be reframed.

Biomarkers and Trial Data on SGLT2 Inhibitors, Finerenone, and GLP-1s

Participants in both forums discussed the H2FPEF score for identifying heart failure with preserved ejection fraction, with Valika citing data showing that body mass index above 30, hypertension, and paroxysmal atrial fibrillation alone confer a 90% probability of the diagnosis. Urine albumin-to-creatinine ratio came up in both sessions as an underused marker. Valika noted that even a normal estimated glomerular filtration rate does not rule out elevated cardiovascular risk once microalbuminuria is present, with every 0.4 mg/mmol increase in the ratio raising heart failure risk by nearly 11%, while Minneapolis participants said the test is rarely ordered outside established diabetes or chronic kidney disease indications.

Discussion in both cities converged on recent trial data reshaping the four pillars of guideline-directed therapy. Finerenone reduced the composite of cardiovascular death and total heart failure events by 16% in the 6,000-patient FINEARTS-HF trial among patients with mildly reduced or preserved ejection fraction, a contrast to the neutral TOPCAT and SPIRIT-HF spironolactone data, with a second spironolactone trial expected to read out later this year.² Participants in both cities noted that dapagliflozin's DELIVER trial included patients with improved ejection fraction while empagliflozin's EMPEROR-Preserved trial did not, a distinction some said factors into prescribing once ejection fraction has recovered.³

Semaglutide's SELECT trial, which enrolled 17,000 patients with established cardiovascular disease, showed consistent benefit across ejection fraction categories for its composite endpoint.⁴ Chicago participants noted a possible signal toward worsening heart failure events with GLP-1 therapy in patients with reduced ejection fraction, a contrast with more favorable heart failure hospitalization data reported in the SUMMIT trial among patients with preserved ejection fraction. In Minneapolis, participants said GLP-1 prescribing in heart failure is outpacing the evidence base and is often initiated by primary care rather than cardiology.

Barriers to Timely Heart Failure Diagnosis and Treatment

Access and education barriers echoed across both forums. Participants described cost and prior authorization as continuing hurdles for finerenone and GLP-1 therapy, alongside a persistent knowledge gap among general cardiologists and primary care clinicians unfamiliar with nonsteroidal mineralocorticoid receptor antagonists. Minneapolis participants added that caregivers are frequently left out of heart failure education despite carrying much of the medication and symptom-monitoring burden, and that hospitalist teams restart or continue guideline-directed therapy inconsistently after discharge.

Both forums closed on a similar note: earlier identification, not just better late-stage treatment, is where the field needs to move next. Participants in Minneapolis pointed to the incoming cardiovascular-kidney-metabolic staging framework and cautioned against discontinuing SGLT2 inhibitors once started, while participants in Chicago emphasized that closing the gap between guideline publication and everyday practice, historically estimated at about a decade, will require primary care, nephrology, and pharmacy to share more of the diagnostic and titration burden long treated as cardiology's alone.

Fonarow GC, Ahmad FS, Ahmad T, et al. HF STATS 2025: heart failure epidemiology and outcomes statistics. An updated 2025 report from the Heart Failure Society of America. 

. Published online 2025. doi:10.1016/j.cardfail.2025.07.007

Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. 

Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. 

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. 

Heart failure classification and staging are being actively reworked as HFpEF approaches or surpasses HFrEF prevalence in US practice, driven by obesity and metabolic syndrome. Clinicians are emphasizing earlier detection in underdefined stage A/B populations and integrating the AHA cardiovascular-kidney-metabolic framework to reflect overlapping cardiometabolic and renal disease. Biomarker and risk-score tools (H2FPEF, urine albumin-to-creatinine ratio) were highlighted alongside evolving evidence for SGLT2 inhibitors, finerenone, and GLP-1 therapies, amid access and implementation gaps.

A pair of clinical forums examined new CKM staging, SGLT2 and MRA trial data, and the barriers delaying heart failure treatment.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Heart Failure Staging and Prevention: Perspectives From Clinical Forums

In this interview, Lawrence Eichenfield, MD, reviews new data on topical and systemic treatments such as tapinarof and ruxolitinib in atopic dermatitis.

New Nonsteroidal Options Expand for Pediatric Atopic Dermatitis

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

Brad Rovin, MD, discusses gaps in IgA nephropathy care, biopsy's expanding role, and how new B cell therapies are reshaping treatment.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Closing Gaps in IgA Nephropathy Diagnosis and Treatment, With Brad Rovin, MD

In this discussion, Eichenfield discusses which advances in eczema he sees as most impactful and where unmet needs remain for pediatric patients.

Q&A: Where the Pediatric Atopic Dermatitis Systemic Pipeline Stands

Podcasts

Once-weekly insulin icodec hits US pharmacies, simplifying basal dosing for type 2 diabetes with new titration rules and promising A1c results.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Weekly Insulin Icodec Now Available for Type 2 Diabetes

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Insulin Icodec Now Available for Type 2 Diabetes in US

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The FDA accepted EIT Pharma’s lonafarnib NDA for chronic hepatitis D, supported primarily by the phase 3 D-LIVR trial.

FDA News

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Hepatology

Lonafarnib NDA Enters FDA Review for Chronic Hepatitis D

In "2025 KDIGO Updates in IgAN: Dual Pathways and New Targets," the panel examines the guideline changes reshaping practice.

2025 KDIGO Updates in IgAN: Dual Pathways and New Targets

A treatable trait is easier to endorse than to define. The panel works through what qualifies, and why extrapulmonary traits deserve the same attention as the airway itself.

Video Series

Treatable Traits in Asthma: Targeting Comorbidities Beyond the Lung

This episode, "Biomarkers in IgAN: Why Hematuria and GFR Slope Matter," features the panel scrutinizing the tools they rely on.

Latest News

New Patch Pump Options Highlighted at ADCES 2026

Age-Specific Criteria Improve Anaphylaxis Detection in Infants

Antibiotic Pretreatment Improves FMT Response in Peanut Allergy

Q&A: First Pediatric Eczema Guidelines and New Topical Options Down to Age 2

Heart Failure Staging and Prevention: Perspectives From Clinical Forums